<?xml version="1.0" encoding="UTF-8"?>
<fig id="F4" position="float">
 <label>Figure 4</label>
 <caption>
  <p>Summarized scheme with proposed acting targets of anti-SARS-CoV-2 in the replication cycle of the virus. Inhibitors of cell entry: inhibitors of angiotensin-converting enzyme 2 (ACE2Is) and antimalarial drugs: chloroquine, hydroxychloroquine; inhibitors of transmembrane protease/serine subfamily member 2 (TMPRSS2): camostate; Inhibitors of replication, membrane fusion, and assembly of SARS-CoV-2: remdesivir, lopinavir/ritonavir combination, umifenovir; humanized monoclonal antibody IgG1 anti-human receptor for interleukin-6 (IL-6): tocilizumab.</p>
 </caption>
 <graphic xlink:href="fpubh-08-00281-g0004" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</fig>
